1.Effect of different nursing modes in different wards
Chinese Journal of Modern Nursing 2013;19(24):2967-2969
Objective To discuss the implementation of different nursing modes in different wards,so as to provide comprehensive,full course and consistent nursing for patients.Methods Multiple nursing modessuch as fixed-nurse,inter-group,overall and dailycontractual liability were adopted and combined in wards of neurology,gastroenterology and otorhinolaryngology to assure the consistence of nursing.Qualification rate of first grade nursing,incidence rate of accident events and nursing complications,understanding rate of health education,qualification rate of nursing document and satisfaction rate of patients were compared before and after the implementation.Results After implementation of diversified nursing modes,the qualification rate of first grade nursing,understanding rate of health education,qualification rate of nursing document had all improved to some extent,while the incidence rate of accident events and nursing complications had declined,and the differences were statistically significant (P < 0.05).After implementation of diversified nursing modes,patients' satisfaction rate in departments of neurology,gastroenterology and otorhinolaryngology had also improved,respectively from 91.67%,89.17%,90.00% to 98.33%,96.67%,97.50%,and the differences were statistically significant (x2 =5.614,5.128,5.760,respectively ; P < 0.05).Conclusions Diversified nursing modes in different wards can improve the quality of nursing,satisfaction of patients and core competency of nursing staff,as well as ensure the implementation of holistic nursing effectively.
2.Treatment of psoriasis vulgaris with a recombinant human tumor necrosis factor receptor:Fc fusion protein:a multicentre,randomized,double blind trial
Qiong HUANG ; Qin-Ping YANG ; Xu FANG ; Ling HAN ; Zhi-Zhong ZHENG ; Wen-Wen FU ; Jian-Fang SUN ; Yi-qun JIANG ; Jun GU ; Chun-fang GUO ; Ai-e Xu ; Jun-fan CHEN ; Bing-hua SU ; Qing-bo HE
Chinese Journal of Dermatology 2003;0(11):-
Objective To investigate the efficacy and tolerability of a recombinant human tumor necrosis factor:Fc fusion protein (rhTNFR:Fc,with a trade name of Yisaipu) in the treatment of moderate to severe psoriasis vulgaris.Methods A multicentre,randomized,double blind,and parallel-controlled trial was performed.One hundred and forty-four patients with moderate to severe psoriasis vulgaris from four centres were randomly assigned and treated with either once-weekly subcutaneous injection of rhTNFR:Fc (50 mg) or oral methotrexate (MTX)(7.5 mg) for 12 weeks.Patients were followed up at 2,4,8,12 weeks after the treatment.Results One hundred and twenty-four patients finished the 12-week course of treat- ment.At 12 weeks after the treatment,a 50%,75%,90% improvement in psoriasis area and severity index (PASI) was achieved by 86.11%,76.39%,52.78% respectively of rhTNFR:Fc-treated patients,and by 63.89%,44.44%,22.22% respectively in MTX-treated patients,and all the three improvement rates were of significant difference between the two groups of patients (all P0.05).Conclusion Compared with MTX,rhTNFR:Fc acts more quickly with a higher cure rate and less toxic reactions in the treatment of psoriasis vulgaris.
3.Analgesic effects of receptin, a chemically modified cobratoxin from Thailand cobra venom.
Hui-Ling ZHANG ; E-mail: ZHQIN5@HOTMAIL.COM. ; Rong HAN ; Zhi-Xing CHEN ; Zhen-Lun GU ; Paul F REID ; Laurence N RAYMOND ; Zheng-Hong QIN
Neuroscience Bulletin 2006;22(5):267-273
Objective To investigate the analgesia induced by receptin (REC), a chemically modified cobratoxin (CTX, a long-chain postsynaptic alpha -neurotoxin from Thailand cobra venom), and the effects of atropine and naloxone on antinociceptive activity of REC in rodent pain models. Methods REC was administered intraperitoneally (5 mg/kg, 7.07 mg/kg, or 10 mg/kg, i.p.) or intra-cerebral venticularly (62.5 mu g/kg, i.c.v.). The antinociceptive action was determined using the hot-plate test, the acetic acid writhing test and tail flick assay in mice and rats. The involvement of cholinergic and the opioid peptidergic systems in REC-induced analgesia were examined by pretreatment of animals with atropine (Atr; 0.5 mg/kg, i.m. or 10 mg/kg, i.p.) or naloxone (Nal; 3 mg/kg, i.p.). The effect of REC on motor activity was tested using the Animex test in mice. Results REC (5 mg/kg, 7.07 mg/kg or 10 mg/kg, i.p.) exhibited a dose-dependent analgesic action in mice as determined with hot-plate test and acetic acid writhing test. The significant analgesia of REC was seen 2 h to 3 h after its administration. In the rat-tail flick assay, the administration of REC at 62.5 mu g/kg (1/160 of systemic dose; i.c.v.) produced marked analgesic effects. Atropine at 0.5 mg/kg (i.m.), 10 mg/kg (i.p.) or naloxone at 3 mg/kg (i.p.) failed to block the analgesic effects of REC. REC at the highest effective dose of 10 mg/kg did not change the spontaneous mobility of mice. Conclusion These results demonstrate that REC has analgesic effect. This activity appears to be mediated through the peripheral nervous system though central nervous system may contribute to REC' s analgesic effects. The central cholinergic system and opioid peptidergic system appear not to be involved in the antinociceptive action of REC.
4.A short-chain alpha-neurotoxin from Naja naja atra produces potent cholinergic-dependent analgesia.
Hui-Ling ZHANG ; E-mail: ZHQIN5@HOTMAIL.COM. ; Rong HAN ; Zhen-Lun GU ; Zhi-Xing CHEN ; Bo-Wen CHEN ; Paul F REID ; Laurence N RAYMOND ; Zheng-Hong QIN
Neuroscience Bulletin 2006;22(2):103-109
Objective To investigate the analgesia induced by cobrotoxin (CT) from venom of Naja naja atra, and the effects of atropine and naloxone on the antinociceptive activity of CT in rodent pain models. Methods CT was administered intraperitoneally (33.3, 50, 75 mu g/kg), intra-cerebral venticularly (2.4 mu g/kg) or microinjected into periaqueductal gray (PAG, 1.2 mu g/kg). The antinoCiceptive action was tested using the hot-plate test and the acetic acid writhing test in mice and rats. The involvement of cholinergic system and the opioid system in CT-induced analgesia was examined by pretreatment of animals with atropine (0.5 mg/kg, im or 10 mg/kg, ip) or naloxone (3 mg/kg, ip). The effect of CT on motor activity was tested using the Animex test. Results CT (33.3, 50 and 75 mu g/kg, ip) exhibited a dosedependent analgesic action in mice as determined with hot-plate test and acetic acid writhing test. In the mouse acetic acid writhing test, the intra-cerebral ventricle administration of CT 2.4 mu g/kg (1/23th of a systemic dose) produced marked analgesic effects. Microinjection of CT 1.2 mu g/kg (1/46th of systemic dose) into the PAG also elicited a robust analgesic action in the hot-plate test in rats. Atropine at 0.5 mg/kg (im) or naloxone at 3 mg/kg (ip) failed to block the analgesic effects of CT, but atropine at 10 mg/kg (ip) did antagonize the analgesia mediated by CT in the mouse acetic acid writhing test. At the highest effective dose of antinociception (75 mu g/kg), CT did not change the spontaneous mobility of mice. Conclusion These results suggest that CT from Naja naja atra venom has analgesic effects. Central nervous system may be involved in CT's analgesic effects and the PAG may be the primary central site where CT exerts its effects. The central cholinergic system but not opioid system appears to be involved in the antinociceptive action of CT.
5.Application of Self-assembling Peptides to Hemostasis.
Hui GAN ; Zhi-Yun MENG ; Zhuo-Na WU ; Xiao-Xia ZHU ; Ruo-Lan GU ; Wen-Zhong SUN ; Gui-Fang DOU
Journal of Experimental Hematology 2015;23(3):903-909
As a widespread phenomenon in living system, molecular self-assembly has become the meeting point of multidisciplinary research including chemistry, biology, materials science and medicine. In recent years, the rapid development in molecular self-assembly of peptide technology is showing a great potential in the application of tissue engineering, drug delivery, bionic medicine, cosmetology field, optical and electronic product development, etc. Especially, the remarkable hemostatic effect of self-assembling peptides (SAP) on organs, nerves and brain wounds successfully promoted its application to the material science and clinical medicine. This review focuses on the hemostatic effects and characteristics of SAP on different bleeding wound models, action mechanism, its benefits and limitations as well as its adrancing trends.
Drug Delivery Systems
;
Hemostasis
;
Humans
;
Peptides
;
Tissue Engineering
6.Correlation between Peripheral Blood Intermediate Monocytes Increased and the Disease Progression of Patients with Diffuse Large BCell Lymphoma.
Quan Quan HU ; Hui Ping WANG ; Kang Sheng GU ; Zhi Min ZHAI ; Yan Li LI
Journal of Experimental Hematology 2022;30(4):1116-1122
UNLABELLED:
AbstractObjective: To explore the distribution characteristics and clinical significance of peripheral blood monocyte subgroups in patients with diffuse large Bcell lymphoma(DLBCL).
METHODS:
The percentage of peripheral blood monocyte subsets of 82 DLBCL patients (including 32 newly diagnosis, 29 remission and 21 relapse) and 30 healthy controls were detected by flow cytometry, and the correlation with the clinical characteristics and its diagnostic value of DLBCL were analyzed.
RESULTS:
The proportion of intermediate monocytes in patients with newly diagnosed DLBCL group was higher than that in healthy controls (t=5.888, P<0.01). The proportion in relapsed group was higher than those in newly diagnosed DLBCL group(t=2.106,P=0.04) and remission group (t=6.882, P<0.01), and the proportion of intermediate monocytes in newly diagnosed DLBCL group was higher than that in Remission group (t=3.969, P<0.01). With the increase of International Prognostic Index (IPI) score, the percentage of intermediate monocytes in patients with DLBCL increased (r=0.37). Furthermore, when the proportion of intermediate monocytes was 10.91% as the cutoff value, the sensitivity and specificity of the whole sample were 90.60% and 9100%, respectively.
CONCLUSION
The disease progression is related to the increased intermediate monocytes, which can be used as a potential diagnostic index for DLBCL.
Antineoplastic Combined Chemotherapy Protocols
;
Disease Progression
;
Humans
;
Lymphoma, Large B-Cell, Diffuse/drug therapy*
;
Monocytes/pathology*
;
Neoplasm Recurrence, Local/pathology*
;
Prognosis
;
Retrospective Studies
7.Regulation Effect of Myeloid Leukemia No.1 Chinese Herb Medicine Prescription Combined with Chemotherapy on Th17 Cells in Bone Marrow of Patients with Acute Myeloid Leukemia.
Guo-Liang ZHANG ; Ming PAN ; Yan-Zhi WANG ; Jian-Xia HUANG ; Gang-Shou GU ; Yan WANG ; Qing WU ; Li-Teng YAO ; Huan-Rong XIE ; Xing-Jiang HU
Journal of Experimental Hematology 2021;29(2):328-332
OBJECTIVE:
To explore the regulation effect of myeloid leukemia No.1 Chinese herb medicine prescription combined with chemotherapy on Th17 cells in bone marrow fluid of AML patients, so as to provide guidance for improving AML treatment effect and patients' long-term survival.
METHODS:
Seventy patients with AML who were hospitalized in Department of Hematology, Wuwei People's Hospital from April 2017 to August 2019 were selected and enrolled in AML group, 25 healthy volunteers were selected and enrolled in control group; then according to therapeutic regimen, AML patients were divided into 2 groups: combined therapy group (myeloid leukemia NO.1 Chinese herb medicine prescription combined with chemotherapy) and non-combined therapy group (chemotherapy alone). Flow cytometry was used to detect the ratio of CD3
RESULTS:
The ratio of CD3
CONCLUSION
Th17 cells expression in bone marrow of newly diagnoses and relapsed AML patients significantly increase, and decrease significantly after treatment. Myeloid leukemia No.1 Chinese herb prescription combined with chemotherapy can significantly increase the CR rate and reduce the RL rate for AML.
Bone Marrow
;
China
;
Humans
;
Leukemia, Myeloid, Acute/drug therapy*
;
Medicine
;
Prescriptions
;
Th17 Cells
;
Vascular Endothelial Growth Factor A
8.High Expression of Bone Marrow VEGF in Patients with Acute Leukemia and Its Correlation with Prognosis.
Ming PAN ; Guo-Liang ZHANG ; Yan-Zhi WANG ; Jian-Xia HUANG ; Gang-Shou GU ; Yan WANG ; Qing WU ; Li-Teng YAO ; Huan-Rong XIE ; Xing-Jiang HU
Journal of Experimental Hematology 2021;29(2):428-432
OBJECTIVE:
To detect the level of vascular endothelial growth factor (VEGF) in bone marrow of patients with non-M3 acute leukemia (AL), and estimate its relationship with prognosis.
METHODS:
From January 2016 to December 2019, 114 patients with AL in department of Hematology, Wuwei People's Hospital were selected as study group, and 25 healthy volunteers were enrolled as control group. The concentration of VEGF in bone marrow was detected by ELISA. The patients were divided into high and low concentration group according to the level of VEGF. The overall survival (OS) and event-free survival (EFS) were compared among different groups.
RESULTS:
The level of VEGF in patients with AL was significantly higher than that in the control group. The median OS and EFS in the low concentration group was 34.5 and 32 months, respectively, while, in the high concentration group was 30 and 26 months, respectively. The differences between the two groups were statistically significant (P=0.010). There were significant differences in OS rate (P=0.035) and EFS rate (P=0.026) between low and high concentration group. Multivariate analysis showed that high VEGF concentration was an independent risk factor affecting OS (HR=2.619, 95%CI 1.070-6.406, P=0.035) and EFS (HR=2.221, 95%CI 1.074-4.552, P=0.031) in AL patients.
CONCLUSION
VEGF highly expresses in the bone marrow of patients with AL at initial diagnosis and relapse, and shows adverse effects on the prognosis.
Bone Marrow
;
Disease-Free Survival
;
Humans
;
Leukemia, Myeloid, Acute
;
Prognosis
;
Vascular Endothelial Growth Factor A
9.Expression Difference of RhoH Gene in Leukemia and Its Clinical Significance.
Jun NI ; Qing-Qing SHI ; Wei WU ; Xin SUN ; Yue-Zhi FANG ; Jian GU
Journal of Experimental Hematology 2019;27(3):758-762
OBJECTIVE:
To investigate the expression and clinical significance of RhoH gene in bone marrow cells of leukemia patients.
METHODS:
31 cases of leukemia and 15 cases of non-tumor as controls were collected. The expression of RhoH in bone marrow cells was detected by real-time quantitative PCR (RQ-PCR). The median expression level of RhoH was used as the cut-off value. The newly diagnosed patients were divided into RhoH high expression group and low expression group. The relationship of different RhoH expression levels with clinical features and prognosis of newly diagnosed patients was analyzed.
RESULTS:
The mRNA expression of RhoH in the bone marrow cells of 31 cases of leukemia was significantly lower than that in the control group, mRNA expression of RhoH in the ALL group was significantly lower than that in AML group (P<0.05). Compared with the RhoH high expression group, the proportion of bone marraw blasts and LDH level in the RhoH low expression group was significantly increased (P<0.05), but there were no significant differences in clinical features such as age, white blood cell count, hemoglobin level, platelets count, PCT and CRP level (P>0.05). In AML, the recurrence rate after standard chemotherapy in RhoH low expression group was higher than that in high expression group, while the expression of RhoH not correlated with other prognostic genes of AML. In ALL, the recurrence rate in RhoH low expression group was not statistically significant different from that in high expression group.
CONCLUSION
RhoH may be involved in the genesis of acute leukemia. In AML, RhoH expression negatively correlates with recurrence rate, which can be used as a prognostic indicator independently. In ALL, RhoH may participate in the disease process through other mechanism.
Acute Disease
;
Bone Marrow
;
Humans
;
Leukemia, Myeloid, Acute
;
genetics
;
Prognosis
;
RNA, Messenger
;
Transcription Factors
;
genetics
;
rho GTP-Binding Proteins
;
genetics
10.MicroRNA-10a expression in FAB different subtype of acute myeloid leukemia and its relationship with drug resistance.
Yong-Jin ZHI ; Feng ZHI ; Rong WANG ; Lian XUE ; Wei-Ying GU ; Biao WANG ; Wei-Min DONG ; Hai-Qian LI ; Yun LING ; Guo-Qiang QIU ; Zhi-Lin WANG ; Xiang-Shan CAO ; Yan LIU
Journal of Experimental Hematology 2015;23(1):29-33
OBJECTIVEThis study was to investigate the expression of miR-10a in the different FAB subtype of acute myeloid leukemia (AML) and its relationship with drug resistance.
METHODSForty de novo patients with AML, 16 patients with non-malignant hematologic disease and three AML cell lines HL-60, U937 and HL-60/ADR were enrolled in this study, the MiR-10a expression in bone marrow mononuclear cells of above-mentioned patients and 3 AML cell lines was detected by TaqMan RT-PCR. The correlation of miR-10a with clinicopathological factors of AML patients was analyzed.
RESULTSThe miR-10a expression level in HL-60 cell line was higher than that in U937 cell line (P = 0.039). And its expression level in de novo AML patients was higher than that in patients with non-malignant hematologic disease (P < 0.01). FAB-AML-M3 patients exhibited higher expression of miR-10a than that in M1, M2 and M4 (P < 0.05); HL-60/ADR cell line showed higher miR-10a expression than that in HL-60 cell line (P < 0.01) . Except M3, the patients without CR (non-CR) after the first cycle of chemotherapy showed a higher level of miR-10a as compared with CR patients (P < 0.01).
CONCLUSIONThe high expression of miR-10a may be closely related to over-proliferation of promyelocyte and drug resistance of acute myeloid leukemia cells, except M3.
Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans ; Leukemia, Myeloid, Acute ; MicroRNAs